(Q38370975)

2 September 2017

1 reference

title

CD19 chimeric antigen receptor T cell therapy for haematological malignancies (English)

1 reference

2 September 2017

Martin Pule

2

0 references

author name string

Sara Ghorashian

series ordinal

1

1 reference

PubMed ID

25753571

2 September 2017

Persis Amrolia

series ordinal

3

1 reference

PubMed ID

25753571

2 September 2017

language of work or name

English

0 references

publication date

5 March 2015

1 reference

British Journal of Haematology

2 September 2017

1 reference

2 September 2017

169

1 reference

2 September 2017

4

1 reference

2 September 2017

463-478

1 reference

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

2 September 2017

1 reference

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

21 January 2018

1 reference

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

21 January 2018

1 reference

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

21 January 2018

1 reference

Small-molecule displacement of a cryptic degron causes conditional protein degradation

21 January 2018

1 reference

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

21 January 2018

1 reference

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

21 January 2018

1 reference

Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.

21 January 2018

1 reference

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

21 January 2018

1 reference

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

21 January 2018

1 reference

The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies

21 January 2018

1 reference

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

21 January 2018

1 reference

Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.

21 January 2018

1 reference

Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems

21 January 2018

1 reference

Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL.

21 January 2018

1 reference

T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.

21 January 2018

1 reference

Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.

21 January 2018

1 reference

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

21 January 2018

1 reference

CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.

21 January 2018

1 reference

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

21 January 2018

1 reference

Inducible apoptosis as a safety switch for adoptive cell therapy

21 January 2018

1 reference

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors

21 January 2018

1 reference

PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses

21 January 2018

1 reference

Novel approaches to enhance the specificity and safety of engineered T cells

21 January 2018

1 reference

Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain

21 January 2018

1 reference

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

21 January 2018

1 reference

A human memory T cell subset with stem cell-like properties

21 January 2018

1 reference

Transcriptional activation by tetracyclines in mammalian cells

21 January 2018

1 reference

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

21 January 2018

1 reference

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

21 January 2018

1 reference

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

21 January 2018

1 reference

Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors

21 January 2018

1 reference

Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy

21 January 2018

1 reference

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

21 January 2018

1 reference

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

21 January 2018

1 reference

Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells

21 January 2018

1 reference

The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.

21 January 2018

1 reference

Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.

21 January 2018

1 reference

The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways

21 January 2018

1 reference

Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.

21 January 2018

1 reference

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans

21 January 2018

1 reference

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

Gene-engineered T cells for cancer therapy

21 January 2018

1 reference

Are natural killer cells superior CAR drivers?

21 January 2018

1 reference

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

21 January 2018

1 reference

Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor

21 January 2018

1 reference

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

21 January 2018

1 reference

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

21 January 2018

1 reference

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

21 January 2018

1 reference

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

21 January 2018

1 reference

Chimeric antigen receptor T cells for sustained remissions in leukemia

21 January 2018

1 reference

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

21 January 2018

1 reference

A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy

21 January 2018

1 reference

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.

21 January 2018

1 reference

Artificial T-cell receptors

21 January 2018

1 reference

A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells

21 January 2018

1 reference

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

21 January 2018

1 reference

Adoptive immunotherapy for cancer: harnessing the T cell response

21 January 2018

1 reference

Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition

21 January 2018

1 reference

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

21 January 2018

1 reference

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

21 January 2018

1 reference

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

21 January 2018

1 reference

Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells

21 January 2018

1 reference

21 January 2018

1 reference

An inducible caspase 9 safety switch for T-cell therapy

21 January 2018

1 reference

A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease

21 January 2018

1 reference

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

21 January 2018

1 reference

The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies

21 January 2018

1 reference

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

21 January 2018

1 reference

Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials

21 January 2018

1 reference

Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.13340

1 reference

2 September 2017

1 reference

PubMed ID

25753571